Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes

被引:76
作者
Mojiminiyi, O. A.
Abdella, N. A.
Al Arouj, M.
Ben Nakhi, A.
机构
[1] Kuwait Univ, Fac Med, Dept Pathol, Safat 13110, Kuwait
[2] Kuwait Univ, Fac Med, Dept Med, Safat 13110, Kuwait
[3] Dept Minist Hlth, Safat, Kuwait
关键词
adiponectin; insulin resistance; metabolic syndrome; Type; 2; diabetes;
D O I
10.1038/sj.ijo.0803355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Obesity and the metabolic syndrome have emerged as clinical and public health crises in many populations, but not all obese patients have the syndrome. As adipocytes produce several adipokines that modulate insulin action as well as glucose and lipid metabolism, we postulate that estimation of adipokines may be useful addition to the criteria used to identify obese individuals with the metabolic syndrome. Objective: To evaluate the determinants and associations of plasma adiponectin in relation to the metabolic syndrome in patients with Type 2 diabetes. Design: Cross-sectional study. Setting: General Teaching Hospital. Patients: One hundred and thirty five ( 57 M, 78 F) patients with Type 2 diabetes mellitus. Measurements: Adiponectin, leptin, high-sensitivity C-reactive protein (hs-CRP), fasting plasma insulin, glucose, glycated hemoglobin and full lipid profile. Patients were classified on the basis of the degree of adiposity, insulin resistance (IR) (homeostasis model assessment of insulin resistance (HOMA-IR)) and the number of the American Heart Association and the National Heart, Lung and Blood Institute criteria of the metabolic syndrome. Results: Adiponectin levels were inversely correlated with age, indices of obesity, IR and hs-CRP. Overweight/obese and non-obese insulin-sensitive patients had significantly higher (P < 0.05) adiponectin levels than those with IR despite similar body mass index and waist circumference. Therefore, within each category of obesity stratification, lower adiponectin levels were associated with IR. Adiponectin showed stepwise decrease with increasing number of the criteria for diagnosis of the metabolic syndrome. Using multiple logistic regression, the odds ratio of the metabolic syndrome as predicted by adiponectin was 0.73 (95% confidence interval 0.53-0.96; P = 0.04). At cutoff point of 18 ng/ml, the diagnostic sensitivity and specificity of adiponectin for the metabolic syndrome were 83 and 65%, respectively, in male patients and 92 and 41%, respectively, in female patients. Receiver operating characteristic analysis showed that adiponectin had significantly higher area under the curve compared with leptin, leptin: adiponectin ratio and triglycerides for the detection of the metabolic syndrome. Conclusions: In patients with Type 2 diabetes, adiponectin concentrations are closely related to IR and the components of the metabolic syndrome. Adiponectin concentration may be a useful addition to the criteria used for identifying obese subjects with the metabolic syndrome.
引用
收藏
页码:213 / 220
页数:8
相关论文
共 40 条
[1]   Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women [J].
Abbasi, F ;
Lamendola, C ;
McLaughlin, T ;
Hayden, J ;
Reaven, GM ;
Reaven, PD .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (03) :280-283
[2]   Plasma insulin concentration is more tightly linked to plasma leptin concentration than is the body mass index [J].
Abbasi, F ;
Carantoni, M ;
McLaughlin, T ;
Reaven, GM .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (04) :544-547
[3]   Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance [J].
Abdella, NA ;
Mojiminiyi, OA ;
Moussa, MA ;
Zaki, M ;
Al Mohammedi, H ;
Al Ozairi, ESS ;
Al Jebely, S .
DIABETIC MEDICINE, 2005, 22 (03) :278-285
[4]  
Al-Isa Abdulwahab Naser, 2003, Nutrition and Health (Bicester), V17, P185
[5]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[6]  
Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1
[7]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[8]  
Balkau B, 1999, DIABETIC MED, V16, P442
[9]   Adiponectin: More than just another fat cell hormone? [J].
Chandran, M ;
Phillips, SA ;
Ciaraldi, T ;
Henry, RR .
DIABETES CARE, 2003, 26 (08) :2442-2450
[10]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252